Earnings Feed
Start Free
Home/Filings/4/0001181431-14-035080
4//SEC Filing

Transcept Pharmaceuticals Inc 4

Accession 0001181431-14-035080

CIK 0001178711operating
View on SEC.govCompany Profile

Filed

Oct 29, 8:00 PM ET

Accepted

Oct 30, 7:00 PM ET

Size

18.2 KB

Accession

0001181431-14-035080

Insider Transaction Report

Form 4
Period: 2014-10-30
Transcept Pharmaceuticals IncTSPT
RAAB G KIRK
Director
Transactions
  • Disposition to Issuer

    Stock option (right to buy)

    2014-10-30−416→ 0 total
    Exercise: $82.56Exp: 2020-01-14→ Common stock (416 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-10-30−1,458→ 0 total
    Exercise: $80.88Exp: 2020-02-03→ Common stock (1,458 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-10-30−3,166→ 0 total
    Exercise: $82.44Exp: 2021-02-02→ Common stock (3,166 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-10-30−1,666→ 0 total
    Exercise: $38.04Exp: 2019-01-30→ Common stock (1,666 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-10-30−3,750→ 0 total
    Exercise: $81.12Exp: 2022-02-01→ Common stock (3,750 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-10-30−5,208→ 0 total
    Exercise: $48.84Exp: 2023-01-07→ Common stock (5,208 underlying)
Holdings

  • Common stock

    9,882
Footnotes (7)
  • [F1]Number of shares accounts for the effect of a reverse stock split of Issuer's common stock at a ratio of one new share for every twelve shares outstanding effective just prior to the effective time of the merger of Paratek Pharmaceuticals, Inc. into a wholly owned subsidiary of the Issuer (the "Merger") pursuant to that certain Agreement and Plan of Merger and Reorganization ("Merger Agreement") by and among Issuer, Tigris Merger Sub, Inc., Tigris Acquisition Sub, LLC, and Paratek,Pharmaceuticals, Inc. ("Paratek") dated June 30, 2014 (the "stock split").
  • [F2]Represents the adjusted stock option exercise price reflecting the Stock Split.
  • [F3]Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, certain outstanding options to purchase Issuer's common stock, whether vested or unvested, with an exercise price higher than the Issuer Closing Price (as defined therein), which is $21.588, were cancelled.
  • [F4]Fully exercisable.
  • [F5]The option vests in forty-eight equal monthly installments beginning on February 27, 2011.
  • [F6]The option vests in forty-eight equal monthly installments beginning on February 24, 2012.
  • [F7]The option vests in forty-eight equal monthly installments beginning on February 7, 2013.

Documents

1 file

Issuer

Transcept Pharmaceuticals Inc

CIK 0001178711

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001178711

Filing Metadata

Form type
4
Filed
Oct 29, 8:00 PM ET
Accepted
Oct 30, 7:00 PM ET
Size
18.2 KB
View on SEC.gov